google-site-verification: googlec7193c3de77668c9.html

NHS patients in England can have life-saving heart drug tafamidis

About 1,500 people in England with ATTR-CM could now be eligible for the treatment.

This rare heart condition typically starts to show in adulthood and gets worse over time as the heart tissue thickens and stiffens.

Its symptoms include:

  • shortness of breath

  • palpitations and abnormal heart rhythms

  • ankle swelling, fatigue, fainting and chest pain

Ultimately, it can cause heart failure.

Prof Simon Ray, national clinical director for heart disease at NHS England, said: ”A first of its kind, tafamidis will give those living with this rare progressive condition new hope.

“This pioneering drug is just one example of the NHS delivering on its commitment to ensure patients across the country have access to the latest and most effective treatments to help significantly improve their quality of life.”

The list price for a packet of 30 capsules of the drug is about £10,000, but Pfizer has a commercial agreement for NHS use which will be less, although the cost has not been made public.


Source link

Advertisements

See also  How an Alzheimer's risk gene disrupts brain circuits long before memory loss

Check Also

Balaghat, Madhya Pradesh: The children dying in India’s remote tribal heartland

Once the outbreak was recognised, health workers began door-to-door screening in affected villages. Mobile medical …

Experimental drug may reduce lymphedema swelling and scarring

[ Credit: Unsplash Matthew Holbreich was a senior in college when the swelling started. He …

Real-world findings suggest GLP-1 drugs offer health benefits for young people with diabetes

[ Credit: Abstract 788: Use of GLP-1-RA in children, adolescents and young adults with type …

Leave a Reply

Available for Amazon Prime